Abstract
The objective of this study was to analyze the clinical, laboratorial, and therapeutical response of polymyalgia rheumatica (PMR) to anti-tumor necrosis factor (anti-TNF) treatment. We systematically searched English articles on the subjects of PMR who were treated with TNF blockers in Pubmed from 1994 to 2010. In addition, we reported on two patients with PMR who were treated by the Rheumatology Division of the Hospital das Clínicas da Faculdade de Medicina da Universidade in São Paulo, Brazil. Ninety-nine cases of patients with PMR treated with anti-TNF were reviewed. The age of these patients ranged from 63 to 84 years, and 70.7% of them were female. Disease duration varied from 10.5 weeks to 95 months, and time of follow-up varied from 2 weeks to 21 months. Infliximab was the anti-TNF of choice in three studies, while etanercept was in five. Time to response varied from 2 to 8 weeks. After anti-TNF treatment, prednisone reduction was observed in all studies. Clinical improvement was found in 7/7 studies, and laboratory improvement of at least 50% of inflammatory markers was observed in 6/7 studies. This study demonstrated a good clinical and laboratory response to anti-TNF therapy in patients with PMR, with or without glucocorticoid.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Salvarani C, Cantini F, Hunder GG (2008) Polymyalgia rheumatica and giant cell arteritis. Lancet 372:234–245
Salvarani C, Cantini F, Niccoli L, Catanoso MG, Macchioni P, Pulsatelli L et al (2003) Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study. J Rheumatol 30:760–763
Ayoub WT, Franklin CM, Torretti D (1985) Polymyalgia rheumatica. Duration of therapy and long-term outcome. Am J Med 79:309–315
Dasgupta B, Dolan AL, Panayi GS, Fernandes L (1998) An initially double-blind controlled 96 week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica. Br J Rheumatol 37:189–195
Cimmino MA, Parodi M, Caporali R, Montecucco C (2006) Is the course of steroid-treated polymyalgia rheumatica more severe in women? Ann N Y Acad Sci 1069:315–321
van der Veen MJ, Dinant HJ, van Booma-Frankfort C, van Albada-Kuipers GA, Bijlsma JW (1996) Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis 55:218–223
Migliore A, Massafra U, Carloni E, Padalino C, Martin Martin S, Lasaracina F et al (2005) TNF-alpha blockade induce clinical remission in patients affected by polymyalgia rheumatica associated to diabetes mellitus and/or osteoporosis: a seven cases report. Eur Rev Med Pharmacol Sci 9:373–378
Salvarani C, Macchioni P, Manzini C, Paolazzi G, Trotta A, Manganelli P et al (2007) Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Intern Med 146:631–639
Catanoso MG, Macchioni P, Boiardi L, Pipitone N, Salvarani C (2007) Treatment of refractory polymyalgia rheumatica with etanercept: an open pilot study. Arthritis Rheum 57:1514–1519
Corrao S, Pistone G, Scaglione R, Colomba D, Calvo L, Licata G (2009) Fast recovery with etanercept in patients affected by polymyalgia rheumatica and decompensated diabetes: a case-series study. Clin Rheumatol 28:89–92
Dasgupta B, Salvarani C, Schirmer M, Crowson CS, Maradit-Kremers H, Hutchings A, members of the American College of Rheumatology Work Group for Development of Classification Criteria for PMR et al (2008) Developing classification criteria for polymyalgia rheumatica: comparison of views from an expert panel and wider survey. J Rheumatol 35:270–277
Salvarani C, Macchioni P, Boiardi L (1997) Polymyalgia rheumatica. Lancet 350:43–47
Kyle V, Hazelman BL (1990) Stopping steroids in polymyalgia rheumatica and giant cell arteritis. BMJ 300:344–345
Cutolo M, Montecucco CM, Cavagna L, Caporali R, Capellino S, Montagna P et al (2006) Serum cytokines and steroidal hormones in polymyalgia rheumatica and elderly-onset rheumatoid arthritis. Ann Rheum Dis 65:1438–1443
Kreiner F, Galbo H (2010) Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial. Arthritis Res Ther 12:R176
Salvarani C, Cantini F, Boiardi L, Hunder GG (2002) Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 347:261–271
Dasgupta B, Borg FA, Hassan N, Barraclough K, Bourke B, Fulcher J et al (2010) BSR and BHPR standards, guidelines and audit Working Group. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford) 49:186–190
Acknowledgments
JF Carvalho, RM Pereira, and E Bonfa received grants from the Federico Foundation and CNPq (300665/2009-1 to JFC, 300559/2009-7 to RMRP, and 305468/2006-5 to EB).
Disclosures
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Aikawa, N.E., Pereira, R.M.R., Lage, L. et al. Anti-TNF therapy for polymyalgia rheumatica: report of 99 cases and review of the literature. Clin Rheumatol 31, 575–579 (2012). https://doi.org/10.1007/s10067-011-1914-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-011-1914-z